

CT:VQ™ commercial rollout commences at Stanford and AstraZeneca expands partnership across Brazil

22 October 2025

Highlights

- Less than two months after FDA clearance, Stanford University becomes the first U.S. Academic Medical Centre (AMC) to adopt CT:VQ™ under a commercial contract
- 4DMedical and AstraZeneca expand the Lung Health Screening Program in Brazil to five additional hospitals, covering 38,000 CT scans annually

Melbourne, Australia, 22 October 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), a global leader in respiratory imaging technology, today announces that Stanford University has become the first Academic Medical Centre (AMC) to adopt CT:VQ™ commercially following FDA clearance, expanding its existing agreement with 4DMedical. The Company also announces the expansion of its AstraZeneca Lung Health Screening Program in Brazil to five additional hospitals.

CT:VQ™ commercial rollout commences at Stanford

Part of Stanford Medicine, the 3D Quantitative Imaging Laboratory (3DQ Lab) is one of the world’s most respected centres for medical imaging research and innovation. Stanford’s adoption of CT:VQ™ marks a significant milestone, representing the first U.S. AMC to commercially implement 4DMedical’s FDA-cleared CT:VQ™ technology in a live clinical environment.

The expanded agreement builds on Stanford's existing relationship with 4DMedical, which allows for up to 20,000 CT scan analyses annually across the Company's advanced suite of solutions, including CT LVAS™ and IQ-UIP™. The addition of CT:VQ™ under a pay-per-scan model enables Stanford to access reimbursement pathways, accelerating clinical adoption and real-world evidence generation.

Stanford's commercial deployment marks the beginning of 4DMedical's planned rollout strategy across a network of Key Opinion Leader (KOL) sites at leading U.S. AMCs. These institutions will serve as critical reference points for clinical validation, physician education, and broader market adoption of CT:VQ™. By demonstrating the technology's transformative potential in cardiothoracic imaging at world-leading centers like Stanford, 4DMedical is positioning CT:VQ™ to establish a new standard of care, replacing nuclear medicine VQ scans with a contrast-free, workflow-integrated alternative that delivers superior resolution and patient accessibility.

Brazilian lung health screening program with AstraZeneca adds five new hospitals

Building on the initial rollout at Hospital Madre Teresa in Belo Horizonte, 4DMedical and AstraZeneca are rapidly expanding their Lung Health Screening Program across Brazil with the addition of five new hospitals, representing an annual volume of approximately 38,000 additional CT scans.

The new hospitals include four in São Paulo: Hospital 9 de Julho (H9J), Hospital Samaritano (HSH), Hospital Alvorada Moema (HAM), Hospital Santa Catarina (HSC), as well as Unimed Joinville (UJ) in Joinville, Santa Catarina. Together, these hospitals deliver a balanced network of high-volume urban and regional centres, supporting program scalability and data diversity.

The future of
lung health

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



The program leverages 4DMedical's advanced imaging analytics to screen for lung cancer and detect incidental findings such as coronary artery calcification and early-stage COPD. By combining 4DMedical's technology with AstraZeneca's commitment to advancing respiratory health, the initiative aims to improve early detection and management of lung disease, providing clinicians with actionable insights to optimise patient care and outcomes.

4DMedical MD/CEO and Founder Andreas Fouras said:

Our partnership with AstraZeneca continues to gain exceptional momentum. The expansion of the Brazilian Lung Health Screening Program to five additional hospitals, within just weeks of launch, demonstrates both the scalability of our platform and its growing importance in large-scale population health initiatives.

Stanford's transition to a full commercial CT:VQ™ contract, less than two months after FDA clearance, represents a powerful validation of our go-to-market strategy. As a globally respected leader in clinical innovation and lung imaging, Stanford serves as an ideal anchor for our CT:VQ™ commercialisation approach: establishing a network of opinion leading sites across key U.S. AMCs to accelerate awareness, adoption, and confidence in CT:VQ™ as the new standard of care in pulmonary imaging. We are immensely proud to have Stanford as the first AMC to implement CT:VQ™ following FDA clearance.

The momentum we are experiencing demonstrates the interest and excitement in CT:VQ™ from healthcare providers, creating a fundamental shift in our trajectory post-FDA clearance. We are on track for an extremely strong FY26, and I look forward to sharing further progress with shareholders ahead of RSNA in November.

—ENDS—

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com